Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 3/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 2/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 6/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 3/20 | 0.34 |
| ▸ | PRKACG | P22612 | 3/20 | 0.34 |
| ▸ | PRKACB | P22694 | 3/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675764 | 0.80 | NEK2 (0.49) | NEK2PLK1CHUKIKBKBAKT2 | |
| SCHEMBL2938674 | 0.78 | JAK2 (0.54) | AKT2JAK2PRKACAPRKACGPRKACB | |
| SCHEMBL12675762 | 0.77 | NEK2 (0.49) | NEK2PLK1CHUKIKBKBAKT2 | |
| SCHEMBL4920755 | 0.76 | PRMT1 (0.44) | JAK2 | |
| SCHEMBL1904661 | 0.76 | NEK2 (0.71) | NEK2PLK1 | |
| SCHEMBL12675760 | 0.76 | NEK2 (0.43) | NEK2PLK1JAK2KITROCK2 | |
| SCHEMBL1904658 | 0.76 | NEK2 (0.71) | NEK2PLK1 | |
| SCHEMBL1900510 | 0.75 | NEK2 (0.58) | NEK2PLK1AKT2PRKACAPRKACG | |
| SCHEMBL2561791 | 0.75 | JAK2 (0.64) | CHUKIKBKBJAK2PRKACAKIT | |
| SCHEMBL14682578 | 0.75 | NEK2 (0.57) | NEK2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| EP-2558099-A2 | KINASE INHIBITORS | The Regents Of The University Of California, San Francisco (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035325-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | NEK2 79/4885PLK1 43/4885CHUK 26/4885 |
| US-20150045343-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | NEK2 79/4885PLK1 43/4885CHUK 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.